New Review on the International Journal of Molecular Sciences

The PI3K/AKT/mTOR pathway is one of the signaling cascades most commonly hijacked by cancer cells. Lymphoma cells are no exceptions. Thus, their pharmacological targeting is being extensively explored. Following their previous work with the dual PI3K/mTOR inhibitor bimiralisib (PQR309) (PMID: 29066507), Dr Chiara Tarantelli and Prof. Francesco Bertoni from IOR, together with PD Anastasios Stath...
More

Pfizer Prize 2020, awards for IOR and IRB researchers in oncology and neurology

The awards for the 29th Pfizer Prize for Research were given on Thursday, February 6, in Zurich. Among the winners were Daniela Latorre, former researcher at the Institute for Research in Biomedicine (IRB) affiliated to USI Università della Svizzera italiana and currently researcher at ETH Zurich, and Arianna Calcinotto of the Institute of Oncological Research (IOR), also affiliated to the U...
More

A new publication by Prof. Francesco Bertoni LAB

Antibody-drug conjugates (ADCs) are an effective therapeutic modality to deliver potent cytotoxic molecules to tumor cells bearing a specific antigen. Following their previous work on the anti-CD19 ADCs huB4-DGN462 and coltuximab ravtansine (SAR3419) (PMID 30733273), the research team led by Prof. Francesco Bertoni has now characterized the novel ADC MEN1309/OBT076 targeting CD205 for its anti- ly...
More

New publication by Giuseppina Carbone’s Prostate Cancer Biology group

A new study, published in the journal Cancers describes a novel approach to dissect the intrinsic heterogeneity of prostate tumors and provide predictive information on clinical outcome and treatment response in clinical samples and experimental models. This prostate-specific metagene approach can improve treatment selection and clinical management of prostate cancer patients. Sarah N. Mapelli,...
More

Mitochondrial reprogramming heads stem cell expansion and castration-resistance in prostate cancer – New grant awarded to Prof. Carlo Catapano

New grant awarded by the Swiss Cancer League to the Tumor Biology and Experimental Therapeutics Group headed by the IOR Director Prof. Carlo Catapano. The 3-year project aims at exploring the role of mitochondria in prostate cancer progression and resistance to current therapies. Project details Project ID: KLS-4899-08-2019 PI: Carlo Catapano Project title: Mitochondrial dynamics at the...
More